The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer

被引：113

作者：

Ryan, Paula D. ^{[1
]}

Goss, Paul E. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

ONCOLOGIST | 2008年 / 13卷 / 01期

关键词：

insulin-like growth factor-I; insulin-like growth factor-II; insulin-like growth factor-I receptor; breast cancer; review;

D O I：

10.1634/theoncologist.2007-0199

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The insulin-like growth factor signaling pathway is important in many human cancers based on data from experimental models as well as epidemiological studies. Important therapies targeted at this pathway have been or are being developed, including monoclonal antibodies to the insulin-like growth factor-I receptor and small molecule inhibitors of the tyrosine kinase function of this receptor. These investigational therapies are now being studied in clinical trials. Emerging data from phase I trials are encouraging regarding the safety of the monoclonal antibodies. In this manuscript, the rationale for targeting the insulin-like growth factor system is reviewed in addition to a summary of the available clinical trial data.

引用

页码：16 / 24

页数：9

共 91 条

[61] Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus [J].